Defining and measuring negative symptoms of schizophrenia in clinical trials

Abstract Recent attention has focused on negative symptoms as a target for new therapeutic approaches including pharmacological agents, medical devices, and psychosocial treatments. Each of these approaches requires an instrument for measuring the severity of negative symptoms as well as changes in...

Full description

Saved in:
Bibliographic Details
Published in:European neuropsychopharmacology 2014-05, Vol.24 (5), p.737-743
Main Authors: Marder, Stephen R, Kirkpatrick, Brian
Format: Article
Language:English
Subjects:
Clinical Trials as Topic - methods
Humans
Internal Medicine
Negative symptoms schizophrenia
Psychiatric Status Rating Scales
Psychiatry
Schizophrenia - diagnosis
Schizophrenia - therapy
Schizophrenic Psychology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Recent attention has focused on negative symptoms as a target for new therapeutic approaches including pharmacological agents, medical devices, and psychosocial treatments. Each of these approaches requires an instrument for measuring the severity of negative symptoms as well as changes in severity over time. The instrument selected should provide coverage for the domains of negative symptoms; it should be sensitive to change; it should be reliable and relatively brief; and it should be useful for large international trials. These criteria were used to evaluate a number of older instruments including the Schedule for the Assessment of Negative Symptoms (SANS), the Positive and Negative Symptoms Scale (PANSS), and the Negative Symptom Assessment Scale (NSA). Two newer scales, the Brief Negative Symptom Scale (BNSS) and the Clinical Assessment Interview for Negative Symptoms (CAINS) were developed following a National Institute of Mental Health consensus meeting and addressed some of the shortcomings of earlier instruments.
ISSN:0924-977X
1873-7862
DOI:10.1016/j.euroneuro.2013.10.016